Colposcopic triage methods for detecting cervical intraepithelial neoplasia grade 3 after cytopathological diagnosis of low-grade squamous intraepithelial lesion: a systematic review on diagnostic tests.

CONTEXT AND OBJECTIVE The age-stratified performance of the oncogenic HPV-DNA (human papillomavirus deoxyribonucleic acid) test for triage of low-grade squamous intraepithelial lesions (LSIL) requires investigation. The objective of this study was to evaluate and compare the age-stratified performance (cutoff point: 35 years) of oncogenic HPV-DNA testing and repeated cytological tests, for detecting cervical intraepithelial neoplasia grade 3 (CIN3), in order to triage for LSIL. DESIGN AND SETTING Systematic review. Studies were identified in nine electronic databases and in the reference lists of the articles retrieved. METHODS The eligibility criteria consisted of initial cytological findings of LSIL; subsequent oncogenic HPV-DNA testing and repeated cytological tests; and CIN3 detection. The Quality Assessment of Diagnostic Accuracy Studies (QUADAS) guidelines were used for quality assessment. Qualitative information synthesis was performed. RESULTS Out of 7,776 studies, 284 were identified as pertinent and three fulfilled the eligibility criteria. The CIN3 prevalence ranged from 6% to 12%. The HPV-DNA positivity rate ranged from 64% to 83%; sensitivity for CIN3 detection ranged from 95.2% to 100%; and specificity was available in two studies (27% and 52%). The sensitivity of repeated cytological tests, in relation to the threshold for atypical squamous cells of undetermined significance (ASCUS), was available in two studies (33% and 90.8%); and specificity was available in one study (53%). CONCLUSIONS Currently, there is no scientific evidence available that would prove that colposcopic triage using oncogenic HPV-DNA testing to detect CIN3 performs better than repeated cytological tests, among women with LSIL aged 35 years and over.

[1]  Mark Schiffman,et al.  ASCUS-LSIL Triage Study , 2000, Acta Cytologica.

[2]  J. Cuzick,et al.  HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. , 2007, European journal of cancer.

[3]  Diane Solomon,et al.  The Bethesda System for reporting cervical/vaginal cytologic diagnoses: revised after the second National Cancer Institute Workshop, April 29-30, 1991. , 1993, Acta cytologica.

[4]  J. Sellors,et al.  Comparison of human papillomavirus DNA testing and repeat Papanicolaou test in women with low-grade cervical cytologic abnormalities: a randomized trial. HPV Effectiveness in Lowgrade Paps (HELP) Study No. 1 Group. , 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[5]  Joakim Dillner,et al.  Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. , 2008, Vaccine.

[6]  M. Schiffman,et al.  Heterogeneity in CIN3 diagnosis. , 2008, The Lancet. Oncology.

[7]  R. Luff,et al.  The Bethesda System for reporting cervical/vaginal cytologic diagnoses. Report of the 1991 Bethesda workshop. , 1992, American Journal of Clinical Pathology.

[8]  M. Mints,et al.  A comparison of the human papillomavirus test and Papanicolaou smear as a second screening method for women with minor cytological abnormalities , 2005 .

[9]  U Menon,et al.  Management of women who test positive for high-risk types of human papillomavirus: the HART study , 2003, The Lancet.

[10]  Diane Solomon,et al.  Chapter 14: Role of triage testing in cervical cancer screening. , 2003, Journal of the National Cancer Institute. Monographs.

[11]  W. Prendiville,et al.  Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis , 2008, BMJ : British Medical Journal.

[12]  David Moher,et al.  An evidence-based practice guideline for the peer review of electronic search strategies. , 2009, Journal of clinical epidemiology.

[13]  J. Dillner,et al.  Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. , 2005, Gynecologic oncology.

[14]  J. Dillner,et al.  Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. , 2006, Vaccine.

[15]  Joan L. Walker A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. , 2003, American journal of obstetrics and gynecology.

[16]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.

[17]  J. T. Cox,et al.  History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[18]  P. Bossuyt,et al.  BMC Medical Research Methodology , 2002 .

[19]  R. Luff,et al.  The Bethesda System for reporting cervical/vaginal cytologic diagnoses. Report of the 1991 Bethesda workshop. , 1992, American journal of clinical pathology.

[20]  J. Peto,et al.  HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial , 2006, British Journal of Cancer.